metformin has been researched along with Hepatitis C in 11 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile." | 9.16 | The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 6.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile." | 5.16 | The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012) |
| " The main risk factors for developing HCC are well known and include hepatitis B and C virus infection, alcohol intake and ingestion of the fungal metabolite aflatoxin B1." | 4.93 | Hepatocellular carcinoma. ( Gores, G; Llovet, JM; Pikarsky, E; Sangro, B; Schwartz, M; Sherman, M; Zucman-Rossi, J, 2016) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 2.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "Hepatocellular carcinoma is the most common primary liver malignancy, commonly a sequelae of hepatitis C infection, but can complicate cirrhosis of any cause." | 1.46 | Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Talebi, A | 1 |
| Kargar, M | 1 |
| Abdel Monem, MS | 1 |
| Farid, SF | 1 |
| Abbassi, MM | 1 |
| Youssry, I | 1 |
| Andraues, NG | 1 |
| Hassany, M | 1 |
| Selim, YMM | 1 |
| El-Sayed, MH | 1 |
| Li, X | 1 |
| Jiao, Y | 1 |
| Xing, Y | 1 |
| Gao, P | 1 |
| Goto, K | 1 |
| Lin, W | 1 |
| Zhang, L | 1 |
| Jilg, N | 1 |
| Shao, RX | 1 |
| Schaefer, EA | 1 |
| Zhao, H | 1 |
| Fusco, DN | 1 |
| Peng, LF | 1 |
| Kato, N | 1 |
| Chung, RT | 1 |
| Llovet, JM | 1 |
| Zucman-Rossi, J | 1 |
| Pikarsky, E | 1 |
| Sangro, B | 1 |
| Schwartz, M | 1 |
| Sherman, M | 1 |
| Gores, G | 1 |
| Doyle, MA | 1 |
| Singer, J | 1 |
| Lee, T | 1 |
| Muir, M | 1 |
| Cooper, C | 1 |
| Kasmari, AJ | 1 |
| Welch, A | 1 |
| Liu, G | 1 |
| Leslie, D | 1 |
| McGarrity, T | 1 |
| Riley, T | 1 |
| Trask, LE | 1 |
| Abbott, D | 1 |
| Lee, HK | 1 |
| Yu, JW | 1 |
| Sun, LJ | 1 |
| Zhao, YH | 1 |
| Kang, P | 1 |
| Yan, BZ | 1 |
| del Campo, JA | 1 |
| García-Valdecasas, M | 1 |
| Rojas, L | 1 |
| Rojas, Á | 1 |
| Romero-Gómez, M | 1 |
| Huang, H | 1 |
| Kang, R | 1 |
| Wang, J | 1 |
| Luo, G | 1 |
| Yang, W | 1 |
| Zhao, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.[NCT02306070] | Phase 2 | 0 participants (Actual) | Interventional | 2016-01-31 | Withdrawn (stopped due to insufficient funding) | ||
| Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal[NCT02660905] | Phase 3 | 25 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Hepatitis C
| Article | Year |
|---|---|
Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis.
Topics: Alcoholism; Diabetes Complications; Diabetes Mellitus; Glucose; Hepacivirus; Hepatitis B; Hepatitis | 2019 |
Hepatocellular carcinoma.
Topics: Aflatoxin B1; Alcohol Drinking; Carcinoma, Hepatocellular; Fibrosis; Hepatitis B; Hepatitis B Vaccin | 2016 |
3 trials available for metformin and Hepatitis C
6 other studies available for metformin and Hepatitis C
| Article | Year |
|---|---|
Hepatoprotective effects of metformin in hepatitis C virus-infected adolescents with beta thalassaemia major.
Topics: Adolescent; beta-Thalassemia; Hepacivirus; Hepatitis C; Humans; Metformin | 2021 |
The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.
Topics: Biopsy; Cell Line; Gene Expression Regulation; Hepacivirus; Hepatitis C; Humans; Liver; Metformin; P | 2013 |
Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
Topics: Adult; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Hepatitis C; Human | 2017 |
Low hemoglobin A(1c)--good diabetic control?
Topics: Anemia; Diabetes Mellitus, Type 2; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C; Humans; | 2012 |
The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance.
Topics: Cell Line; Comorbidity; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regul | 2012 |
Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Autophagy; Autophagy-Related Protein-1 Ho | 2013 |